Indications: blood tumor

Description:

1. It is used for the treatment of leukemia, lymphoma and other blood tumors.

2. Using cytokines as targeting vector, connecting small molecule toxin molecules, targeting tumor cells, ADC design. While maintaining the killing effect on tumor cells, reduce immunogenicity and toxic and side effects; Fusion of HSA nano antibody to improve the half-life in vivo.

3. Compared with the targeted antibody used in ADC drugs at present, the production cost is significantly reduced.

4. The molecular design of this project is innovative and is expected to become the first in class variety for the treatment of leukemia and lymphoma.